Meta-Analysis the Effectiveness of Ivermectin Use on the Length of Stay in Inpatients of COVID-19

Background: COVID-19 is a common problem in global health. disease that infects the respiratory tract caused by Coronavirus virus. Symptoms range from mild to severe and life-threatening pneumonia can occur. At beginning of PSBB, information circulated Ivemectin could treat infections. Ivermectin an antiparasitic drug be used as prophylaxis therapy for coronavirus 2019. alternative because there previous drug, chloroquine, which COVID-19. This study aims estimate effectiveness on duration hospitalization patients with based results similar studies. Subjects Method : meta-analysis following PICO, population: patients. Intervention: ivermectin. Comparison: standard therapy. Outcome: shorter hospital stay. Meta-analyses systematic studies using PubMed, Scopus, Scholar, Springlink, Cochrane, Clinical Key, Science Direct databases. Keywords AND RCT “Coronavirus Disease” “NCOV disease” “COVID-19 treatment”. The article under full-text randomized controlled clinical trial (RCT) design. Articles were collected PRISMA diagrams analyzed Review Manager 5.3. Results A total 9 Randomized Control Trial Europe, America, Asia Africa selected review meta-analysis. receiving decreased stay 1.52 units compared this result was statistically significant (SMD= -1.52; 95% CI= -2.34 -0.70; p= 0.003). Conclusion: reduce Keywords: COVID-19, ivermectin, Correspondence: Masromi Hendria Wijayanto. Masters Program Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Jawa Tengah. Email: masromi­[email protected]. Mobile: 0895402471549. Indonesian Journal Medicine (2022), 07(02): 200-208 https://doi.org/10.26911/theijmed.2022.07.02.08